Nicardipine pellets for the prevention of cerebral vasospasm

Acta Neurochirurgica, Supplementum

Volumn 110, Issue , 2011, Pages 209-211

  Thomé, Claudius ^a   Seiz, Marcel ^a   Schubert, Gerrit Alexander ^a   Barth, Martin ^b   Vajkoczy, Peter ^c   Kasuya, Hidetoshi ^d   Schmiedek, Peter ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Cerebral vasospasm; Intrathecal; Nicardipine; Prolonged release implants; Subarachnoid hemorrhage

Indexed keywords

NICARDIPINE;

ADULT; ANEURYSM RUPTURE; BRAIN ANGIOGRAPHY; BRAIN ARTERY ANEURYSM; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN VASOSPASM; CLINICAL ARTICLE; CLINICAL PROTOCOL; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED DRUG RELEASE; DISEASE SEVERITY; HUMAN; MALE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; SUBARACHNOID HEMORRHAGE;

EID: 85052610193     PISSN: 00651419     EISSN: 00016268     Source Type: Book Series    
DOI: 10.1007/978-3-7091-0356-2_38     Document Type: Conference Paper

References (10)

1. Barth M, Capelle HH, Weidauer S, Weiss C, Münch E, Thomé C, et al. Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid hemorrhage: A prospective, randomized, double-Blind phase IIa study. Stroke 2007;38:330-6
2. Barth M, Pena P, Seiz M, Thomé C, Muench E, Weidauer S, et al. Effect of intraventricular nicardipine prolonged release implants on clinical and radiological outcome in patients following aneurysmal SAH. 2010 (In review
3. Barth M, Thomé C, Schmiedek P, Weiss C, Kasuya H, Vajkoczy P. Characterization of functional outcome and quality of life following subarachnoid hemorrhage in patients treated with and without nicardipine prolonged-release implants. J Neurosurg. 2009;110: 955-60
4. Kasuya H. Clinical trial of nicardipine prolonged-release implants for preventing cerebral vasospasm: Multi-center cooperative study in Tokyo. Abstract book of the 10th international conference on cerebral vasospasm, Chongqing, China, 2009. p. 11
5. Kasuya H, Onda H, Sasahara A, Takeshita M, Hori T. Application of nicardipine prolonged-release implants: Analysis of 97 consecutive patients with acute subarachnoid hemorrhage. Neurosurgery 2005;56:895-902
6. Kasuya H, Onda H, Takeshita M, Okada Y, Hori T. Efficacy and safety of nicardipine prolonged-release implants for preventing vasospasm in humans. Stroke 2002;33:1011-5
7. Krischek B, Kasuya H, Onda H, Hori T. Nicardipine prolongedrelease implants for preventing cerebral vasospasm after subarachnoid hemorrhage: Effect and outcome in the first 100 patients. Neurol Med Chir (Tokyo). 2007;47:389-94
8. Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): Randomized, double-Blind, placebo-controlled phase 2 dose-finding trial. Stroke 2008;39:3015-21
9. Schneider U, Dreher S, Schmiedek P, Kasuya H, Vajkoczy P. The use of nicardipine prolonged release implants (NPRI) in microsurgical clipping after aneurysmal subarachnoid hemorrhage (SAH) -comparison to endovascular coiling. Abstract book of the 60th annual meeting of the german society of neurosurgery, Münster, Germany, 2009. p. 72
10. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: Results of a randomized, double-Blind, placebo-controlled, multicenter phase IIa study. J Neurosurg. 2005;103:9-17